Zogenix to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 6

EMERYVILLE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. ZGNX, a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2018, after the market close, and will host a corporate update conference call and webcast on Monday, August 6, 2018, at 4:30 PM Eastern Time.

Conference Call Details

Monday, August 6^th @ 4:30 PM Eastern Time/1:30 PM Pacific Time

Toll Free:                     800-263-0877

International:               323-794-2094

Conference ID:           1390518

Webcast:                     http://public.viavid.com/index.php?id=130329

Replays, Available through August 20^th:

Domestic:                    844-512-2921

International:               412-317-6671

Replay PIN:                1390518

About Zogenix

Zogenix, Inc. ZGNX is a pharmaceutical company dedicated to developing therapies for people living with severe central nervous system (CNS) disorders who have limited or no treatment options. Led by a team of experts in rare disease development and CNS conditions, Zogenix is rapidly advancing the clinical investigation and development of ZX008 (fenfluramine hydrochloride) for patients with severe, rare epilepsies, including Dravet and Lennox-Gastaut syndromes.

For more information, visit www.zogenix.com.

CONTACT:

Investors:

Andrew McDonald

Founding Partner, LifeSci Advisors LLC

646-597-6987 | Andrew@lifesciadvisors.com